.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
McKesson
Argus Health
Colorcon
Daiichi Sankyo
US Army
Cerilliant
Citi
Dow

Generated: June 27, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,518,987

« Back to Dashboard

Claims for Patent: 8,518,987

Title:Pseudopolymorphic forms of a HIV protease inhibitor
Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypr- opylcarbamate and processes for producing them are disclosed.
Inventor(s): Vermeersch; Hans Wim Pieter (Ghent, BE), Thone; Daniel Joseph Christiaan (Beerse, BE), Janssens; Luc Donne Marie-Louise (Malle, BE), Wigerinck; Piet Tom Bert Paul (Terhagen, BE)
Assignee: Janssen R&D Ireland (Little Island, Co. Cork, IE)
Application Number:12/536,807
Patent Claims: 1. A hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate in which the ratio of the compound to water is about 1:0.5 to about 1:3.

2. A hydrate having the formula: ##STR00002##

3. A composition comprising a hydrate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypr- opylcarbamate, in which the ratio of compound to water is about 1:0.5 to about 1:3, and an inert carrier.

4. The composition of claim 3 wherein the inert carrier is a pharmaceutically acceptable carrier.

5. The composition of claim 4 wherein the pharmaceutically acceptable carrier is a solid inert carrier.

6. A composition comprising a hydrate having the formula: ##STR00003## and an inert carrier.

7. The composition of claim 6 wherein the inert carrier is a pharmaceutically acceptable carrier.

8. The composition of claim 7 wherein the pharmaceutically acceptable carrier is a solid inert carrier.

9. The hydrate of claim 1 wherein the ratio of the compound to water is about 1:1 to about 1:2.

10. The hydrate of claim 1 wherein the ratio of the compound to water is about 1:0.5.

11. The hydrate of claim 1 wherein the ratio of the compound to water is about 1:1.

12. The hydrate of claim 1, wherein the ratio of the compound to water is about 1:2.

13. The hydrate of claim 1 wherein the ratio of the compound to water is about 1:3.

14. The composition of claim 3 wherein the ratio of the compound to water is about 1:1 to about 1:2.

15. The composition of claim 3 wherein the ratio of the compound to water is about 1:0.5.

16. The composition of claim 3 wherein the ratio of the compound to water is about 1:1.

17. The composition of claim 3 wherein the ratio of the compound to water is about 1:2.

18. The composition of claim 3 wherein the ratio of the compound to water is about 1:3.

19. The composition of claim 3 further comprising amorphous (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypr- opylcarbamate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Army
Argus Health
Deloitte
Covington
Baxter
Dow
Teva
Cipla
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot